The US Food and Drug Administration's (FDA) drug regulatory division announced the approval of a new indication for Gilead's Truvada (emtricitabine/tenofovir disoproxil fumarate), making it the first ...
The U.S. Food and Drug Administration on April 21, 2026, approved Merck’s Idvynso, a once-daily combination pill for HIV treatment that pairs two drug classes in a single tablet. The approval gives ...
The FDA has approved Merck’s once-daily, two-drug regimen for adults with virologically suppressed HIV-1. The treatment combines 100 mg doravirine and 0.25 mg islatravir and is indicated for patients ...
Idvysno provides the first complete two-drug regimen that is both non-INSTI–based and tenofovir-free, positioned for switch in stable, suppressed adults meeting resistance and failure-history criteria ...
FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be taken twice a year. On Wednesday, the U.S. Food and Drug Administration ...
IDVYNSO is approved for adults with virologically suppressed HIV-1 with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine IDVYNSO is the ...
Credit: Merck. Idvynso is a new once-daily, two-drug oral regimen for adults with HIV-1 who are virologically suppressed and have no history of treatment failure. Idvynso is a once-daily switch ...
US FDA Approves Merck's Pill Combo to Treat HIV Infection By Christy Santhosh and Sriparna Roy April 21 (Reuters) - The U.S. Food and Drug Administration has approved Merck's once-daily, oral, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results